A Phase 4 interventional study of Diphenhydramine Hydrochloride and Placebo in Occasional Sleeplessness, sponsored by Procter and Gamble. Completed. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-03-15.
Sponsored by Procter and Gamble · Phase 4, Interventional, and Treatment
The present study was conducted to investigate the impact of diphenhydramine hydrochloride on the ability to initiate sleep.
Diphenhydramine hydrochloride (herein referred to as diphenhydramine) is an antihistamine of the ethanolamine classes with known sleep-inducing properties and is approved by the Food \& Drug Administration to reduce the time to sleep onset in individuals having difficulty falling asleep. The goal of the study is to investigate diphenhydramine versus placebo with regard to several sleep parameters, including time to sleep onset, in healthy adult subjects suffering from occasional sleeplessness.
1,856 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 594 are open to participants now.
This study's enrollment of 33 is below the median of 73 across 1,631 interventional studies indexed under Sleep Initiation and Maintenance Disorders.
Browse Sleep Initiation and Maintenance Disorders studies →Procter and Gamble is the lead sponsor of 80 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 10 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Diphenhydramine (50 mg) elixir taken when subjects had trouble falling asleep
Drug: Diphenhydramine Hydrochloride
Placebo elixir taken when subjects had trouble falling asleep
Drug: Placebo
30 mL at bedtime
Also known as: Zzzquil
30 mL at bedtime
Also known as: placebo comparator
Mean Latency to Persistent Sleep
Per Protocol population based on subjects who completed treatment crossover
Time frame: 4 weeks
Participants were recruited at Henry Ford Medical Hospital, Detroit MI, USA between October 2013 to December 2014.
| Milestone | Diphenhydramine Hydrochloride, Then Placebo | Placebo, Then Diphenhydramine Hydrochloride |
|---|---|---|
| Started | 17 | 18 |
| Completed | 12 | 13 |
| Not completed | 5 | 5 |
| Withdrew: Did not meet phase 2 eligibility | 4 | 4 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Milestone | Diphenhydramine Hydrochloride, Then Placebo | Placebo, Then Diphenhydramine Hydrochloride |
|---|---|---|
| Started | 12 | 13 |
| Completed | 12 | 13 |
| Not completed | 0 | 0 |
Per Protocol population based on subjects who completed treatment crossover
| minutes | Diphenhydramine Hydrochloride | Placebo |
|---|---|---|
| Mean Latency to Persistent Sleep | 19.1 ± 3.1 | 27.1 ± 3.1 |
Collected over After informed consent but prior to 1st dose of study drug, only SAEs were collected in the eCRFs (the study had no SAEs). After a patient received his/her first dose of investigational product until his/her exit from the study, all AEs were collected.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Diphenhydramine Hydrochloride | — | 0/30 (0%) | 8/30 (26.7%) |
| Placebo | — | 0/29 (0%) | 7/29 (24.1%) |
| Event | Diphenhydramine Hydrochloride | Placebo |
|---|---|---|
| HeadacheNervous system disorders | 3/30 | 4/29 |
| Back PainMusculoskeletal and connective tissue disorders | 0/30 | 2/29 |
| NasopharyngitisInfections and infestations | 0/30 | 1/29 |
| MigraineNervous system disorders | 1/30 | 1/29 |
| Dry MouthGastrointestinal disorders | 1/30 | 0/29 |
| FatigueGeneral disorders | 1/30 | 0/29 |
| Product Taste AbnormalGeneral disorders | 1/30 | 0/29 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/30 | 0/29 |
| SomnolenceNervous system disorders | 1/30 | 0/29 |
| DysmenorrhoeaReproductive system and breast disorders | 1/30 | 0/29 |
| Age, Continuous(years) | Entire Study Population |
|---|---|
| Mean | 36.2 ± 9.64 |
| Sex: Female, Male(Participants) | Entire Study Population |
|---|---|
| Female | 25 |
| Male | 8 |
| Ethnicity (NIH/OMB)(Participants) | Entire Study Population |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 32 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Entire Study Population |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 2 |
| Native Hawaiian or Other Pacific Islander | 1 |
| Black or African American | 12 |
| White | 17 |
| More than one race | 1 |
| Unknown or Not Reported | 0 |
| Weight(lb) | Entire Study Population |
|---|---|
| Mean | 163.3 ± 34.29 |
| Height(inches) | Entire Study Population |
|---|---|
| Mean | 66.4 ± 3.00 |
| Body Mass Index (BMI)(kg/m2) | Entire Study Population |
|---|---|
| Mean | 25.9 ± 4.81 |
No study locations are listed for this record.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sleep Initiation and Maintenance Disorders→
Procter and Gamble